CN1471392A - 用于治疗神经性及神经心理性疾患的方法 - Google Patents
用于治疗神经性及神经心理性疾患的方法 Download PDFInfo
- Publication number
- CN1471392A CN1471392A CNA01817857XA CN01817857A CN1471392A CN 1471392 A CN1471392 A CN 1471392A CN A01817857X A CNA01817857X A CN A01817857XA CN 01817857 A CN01817857 A CN 01817857A CN 1471392 A CN1471392 A CN 1471392A
- Authority
- CN
- China
- Prior art keywords
- npy
- purposes
- receptor
- anxiety
- lure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 14
- 230000000926 neurological effect Effects 0.000 title claims abstract description 8
- 238000000034 method Methods 0.000 title abstract description 13
- 230000003557 neuropsychological effect Effects 0.000 title 1
- 102400000064 Neuropeptide Y Human genes 0.000 claims abstract description 118
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 36
- 230000036506 anxiety Effects 0.000 claims abstract description 28
- 239000003112 inhibitor Substances 0.000 claims abstract description 22
- 230000001537 neural effect Effects 0.000 claims abstract description 11
- 239000000758 substrate Substances 0.000 claims abstract description 8
- 208000002193 Pain Diseases 0.000 claims abstract description 4
- 206010015037 epilepsy Diseases 0.000 claims abstract description 4
- 201000000980 schizophrenia Diseases 0.000 claims abstract description 4
- 208000000094 Chronic Pain Diseases 0.000 claims abstract 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims abstract 2
- 208000005392 Spasm Diseases 0.000 claims abstract 2
- 206010022437 insomnia Diseases 0.000 claims abstract 2
- 101800003845 Neuropeptide Y Proteins 0.000 claims description 112
- 239000003814 drug Substances 0.000 claims description 11
- 208000028017 Psychotic disease Diseases 0.000 claims description 5
- 229940002612 prodrug Drugs 0.000 claims description 3
- 239000000651 prodrug Substances 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 230000035479 physiological effects, processes and functions Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 46
- 210000004556 brain Anatomy 0.000 abstract description 24
- 201000010099 disease Diseases 0.000 abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 11
- 102000004190 Enzymes Human genes 0.000 abstract description 6
- 108090000790 Enzymes Proteins 0.000 abstract description 6
- 101710151321 Melanostatin Proteins 0.000 abstract description 6
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 abstract description 6
- 230000007423 decrease Effects 0.000 abstract description 4
- 241001465754 Metazoa Species 0.000 abstract description 3
- 230000000949 anxiolytic effect Effects 0.000 abstract description 3
- 108010043412 neuropeptide Y-Y1 receptor Proteins 0.000 abstract description 3
- 230000002035 prolonged effect Effects 0.000 abstract description 3
- 230000009467 reduction Effects 0.000 abstract description 3
- 101710134735 Attractin Proteins 0.000 abstract description 2
- 102100027936 Attractin Human genes 0.000 abstract description 2
- 241000124008 Mammalia Species 0.000 abstract description 2
- 230000001430 anti-depressive effect Effects 0.000 abstract description 2
- 239000002249 anxiolytic agent Substances 0.000 abstract description 2
- 230000002829 reductive effect Effects 0.000 abstract description 2
- 102000001708 Protein Isoforms Human genes 0.000 abstract 1
- 108010029485 Protein Isoforms Proteins 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 230000001364 causal effect Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 230000003001 depressive effect Effects 0.000 abstract 1
- BPGXUIVWLQTVLZ-OFGSCBOVSA-N neuropeptide y(npy) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 BPGXUIVWLQTVLZ-OFGSCBOVSA-N 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 description 35
- 108020003175 receptors Proteins 0.000 description 35
- 239000000523 sample Substances 0.000 description 22
- 239000000203 mixture Substances 0.000 description 17
- 241000700159 Rattus Species 0.000 description 16
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- 102100029909 Peptide YY Human genes 0.000 description 15
- 108010088847 Peptide YY Proteins 0.000 description 15
- 210000003169 central nervous system Anatomy 0.000 description 15
- YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 description 14
- 238000012360 testing method Methods 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 8
- KUWBXRGRMQZCSS-HSZRJFAPSA-N bibp-3226 Chemical compound N([C@H](CCCN=C(N)N)C(=O)NCC=1C=CC(O)=CC=1)C(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1 KUWBXRGRMQZCSS-HSZRJFAPSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 210000003016 hypothalamus Anatomy 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 102100038991 Neuropeptide Y receptor type 2 Human genes 0.000 description 6
- 101710197945 Neuropeptide Y receptor type 2 Proteins 0.000 description 6
- 102000003797 Neuropeptides Human genes 0.000 description 6
- 108090000189 Neuropeptides Proteins 0.000 description 6
- 230000006399 behavior Effects 0.000 description 6
- 238000005336 cracking Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- ARNUPLMOASAEAN-ASLNEKEESA-N (2s,3s)-2-amino-3-methyl-1-(1,3-thiazolidin-2-yl)pentan-1-one Chemical compound CC[C@H](C)[C@H](N)C(=O)C1NCCS1 ARNUPLMOASAEAN-ASLNEKEESA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 210000004884 grey matter Anatomy 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 229940127240 opiate Drugs 0.000 description 5
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 102000012301 Neuropeptide Y receptor Human genes 0.000 description 4
- 240000007594 Oryza sativa Species 0.000 description 4
- 102000018886 Pancreatic Polypeptide Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 230000001734 parasympathetic effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 108010055166 Chemokine CCL5 Proteins 0.000 description 3
- 102000001327 Chemokine CCL5 Human genes 0.000 description 3
- 102100021752 Corticoliberin Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 125000004060 L-alloisoleucine group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 3
- 108050002826 Neuropeptide Y Receptor Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000001353 anxiety effect Effects 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229960005181 morphine Drugs 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000011117 substance-related disease Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- 108010049140 Endorphins Proteins 0.000 description 2
- 102000009025 Endorphins Human genes 0.000 description 2
- 102000018389 Exopeptidases Human genes 0.000 description 2
- 108010091443 Exopeptidases Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 2
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 description 2
- 102400000321 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101100516969 Homo sapiens NPY1R gene Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- 102100038878 Neuropeptide Y receptor type 1 Human genes 0.000 description 2
- 102100029549 Neuropeptide Y receptor type 5 Human genes 0.000 description 2
- 101710198055 Neuropeptide Y receptor type 5 Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000002180 anti-stress Effects 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 150000003943 catecholamines Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- -1 fatty acid ester Chemical class 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000005171 mammalian brain Anatomy 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000002850 nasal mucosa Anatomy 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 210000000956 olfactory bulb Anatomy 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 210000002741 palatine tonsil Anatomy 0.000 description 2
- 108010071588 peptide YY (13-36) Proteins 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000036178 pleiotropy Effects 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000008430 psychophysiology Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 208000020685 sleep-wake disease Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- 230000005062 synaptic transmission Effects 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 150000003668 tyrosines Chemical class 0.000 description 2
- 239000005526 vasoconstrictor agent Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- VBBFIBMVFSUUBP-MERQFXBCSA-N (2S)-1-(2-aminoacetyl)-N-(4-nitrophenyl)pyrrolidine-2-carboxamide hydrochloride Chemical compound Cl.NCC(=O)N1CCC[C@H]1C(=O)NC1=CC=C([N+]([O-])=O)C=C1 VBBFIBMVFSUUBP-MERQFXBCSA-N 0.000 description 1
- CHFOKHTUDAOSOW-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12.N1N=CC=CC2=CC=CC=C12 CHFOKHTUDAOSOW-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 229940122010 Corticotropin releasing factor antagonist Drugs 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 108010092674 Enkephalins Proteins 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 102400000325 Glucagon-like peptide 1(7-36) Human genes 0.000 description 1
- 101800004295 Glucagon-like peptide 1(7-36) Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101001090484 Homo sapiens LanC-like protein 2 Proteins 0.000 description 1
- 101500025005 Homo sapiens Neuropeptide Y Proteins 0.000 description 1
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100034723 LanC-like protein 2 Human genes 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000158728 Meliaceae Species 0.000 description 1
- YFGBQHOOROIVKG-FKBYEOEOSA-N Met-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 YFGBQHOOROIVKG-FKBYEOEOSA-N 0.000 description 1
- 108010042237 Methionine Enkephalin Proteins 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 108010002245 Neuropeptide Y4 receptor Proteins 0.000 description 1
- 102000028435 Neuropeptide Y4 receptor Human genes 0.000 description 1
- 102400001111 Nociceptin Human genes 0.000 description 1
- 108090000622 Nociceptin Proteins 0.000 description 1
- APSUXPSYBJVPPS-YAUKWVCOSA-N Norbinaltorphimine Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC=2C=3C[C@]4(O)[C@]67CCN(CC8CC8)[C@@H]4CC=4C7=C(C(=CC=4)O)O[C@H]6C=3NC=25)O)CC1)O)CC1CC1 APSUXPSYBJVPPS-YAUKWVCOSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229940083963 Peptide antagonist Drugs 0.000 description 1
- 206010034432 Performance fear Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100038931 Proenkephalin-A Human genes 0.000 description 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
- 101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- WBAXJMCUFIXCNI-WDSKDSINSA-N Ser-Pro Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WBAXJMCUFIXCNI-WDSKDSINSA-N 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 1
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- ZSXJENBJGRHKIG-UWVGGRQHSA-N Tyr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 ZSXJENBJGRHKIG-UWVGGRQHSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 239000010692 aromatic oil Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000003938 benzyl alcohols Chemical class 0.000 description 1
- PQKHESYTSKMWFP-WZJCLRDWSA-N beta-Funaltrexamine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@H]3NC(=O)/C=C/C(=O)OC)CN2CC1CC1 PQKHESYTSKMWFP-WZJCLRDWSA-N 0.000 description 1
- RSJAXPUYVJKAAA-JPGJPTAESA-N biie-0246 Chemical compound N([C@@H](CCCN=C(N)N)C(=O)NCCN1C(N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C1=O)=O)C(=O)CC1(CC(=O)N2CCN(CC2)C2C3=CC=CC=C3C(=O)NC3=CC=CC=C32)CCCC1 RSJAXPUYVJKAAA-JPGJPTAESA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940116592 central nervous system diagnostic radiopharmaceuticals Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000002769 corticotropin releasing factor antagonist Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 108700023159 delta Opioid Receptors Proteins 0.000 description 1
- 102000048124 delta Opioid Receptors Human genes 0.000 description 1
- 210000001947 dentate gyrus Anatomy 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000002895 emetic Substances 0.000 description 1
- 230000006397 emotional response Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001400 expression cloning Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 210000001222 gaba-ergic neuron Anatomy 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
- XKWCTHKJQNUFOQ-HRPSIEBRSA-N gtpl1504 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 XKWCTHKJQNUFOQ-HRPSIEBRSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- LDHBWEYLDHLIBQ-UHFFFAOYSA-M iron(3+);oxygen(2-);hydroxide;hydrate Chemical compound O.[OH-].[O-2].[Fe+3] LDHBWEYLDHLIBQ-UHFFFAOYSA-M 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 210000000627 locus coeruleus Anatomy 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001254 matrix assisted laser desorption--ionisation time-of-flight mass spectrum Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000001730 monoaminergic effect Effects 0.000 description 1
- 102000051367 mu Opioid Receptors Human genes 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- DKJCUVXSBOMWAV-PCWWUVHHSA-N naltrindole Chemical compound N1([C@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC2=C3[CH]C=CC=C3N=C25)O)CC1)O)CC1CC1 DKJCUVXSBOMWAV-PCWWUVHHSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000036403 neuro physiology Effects 0.000 description 1
- 239000000712 neurohormone Substances 0.000 description 1
- 239000002660 neuropeptide Y receptor antagonist Substances 0.000 description 1
- 102000008434 neuropeptide hormone activity proteins Human genes 0.000 description 1
- 108040002669 neuropeptide hormone activity proteins Proteins 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- PULGYDLMFSFVBL-SMFNREODSA-N nociceptin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 PULGYDLMFSFVBL-SMFNREODSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 238000011303 olfactory bulbectomy Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 102000014187 peptide receptors Human genes 0.000 description 1
- 108010011903 peptide receptors Proteins 0.000 description 1
- 210000002509 periaqueductal gray Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108010041071 proenkephalin Proteins 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 230000004800 psychological effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000004895 regional blood flow Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002782 sympathoadrenal effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 108010020532 tyrosyl-proline Proteins 0.000 description 1
- 230000001515 vagal effect Effects 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000011680 zucker rat Methods 0.000 description 1
- 108020001612 μ-opioid receptors Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Anesthesiology (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
本发明公开了一种用于治疗动物(包括人)的心身性、抑郁性和神经精神性疾病的治疗方法，所述疾病例如为焦虑、抑郁、失眠、精神分裂、癫痫、痉挛和慢性疼痛。通过施用一种适当的吸诱素(attractin)抑制剂，可引起哺乳动物脑内的吸诱素酶或其异构体的活性下降，并由此导致神经肽Y(neuropeptide Y，NPY)及其类似底物的降解减少。该治疗可减少或减缓具有功能活性的神经元NPY(1－36)的浓度的下降，这导致内源性NPY(1－36)的稳定性增加，其结果是NPY的活性延长，由此导致NPY Y1受体活性功能性活化，从而从而有益于抗抑郁、抗焦虑、止痛、抗高血压以及其他的神经学作用。
Description
发明背景
发明领域
本发明涉及吸诱素(attractin)及其异构体在中枢神经系统(centralnervous system，CNS)内的功能，以及其对神经肽水平、神经传递和行为的生物学作用。本发明还涉及通过选择性抑制吸诱素及其异构体而加强脑内的神经肽Y(Neuropeptide Y，NPY)系统以及吸诱素的其他底物的内源性神经性和神经心理性作用。本发明进一步涉及通过抑制CNS内的吸诱素及其异构体而加强NPY Y1受体介导的效应从而对以下疾病进行治疗：高血压病、发热、睡眠障碍、厌食症、包括抑郁症在内的焦虑相关性疾病、包括癫痫在内的抽搐、药物戒断(drugwithdrawal)和酗酒、包括认知障碍和痴呆在内的神经退行性疾病、以及包括精神分裂症在内的神经精神性疾病。
技术背景NPY的发现过程
神经肽Y(NPY)是一种36个氨基酸的肽，属于胰多肽家族(pancreatic polypeptide family)，最初于1982年在猪脑中被分离出来(Tatemoto和Mutt，1982)。NPY存在于所有支配心血管系统的交感神经中，并且是脑和心脏中含量最丰富的肽。此外，在大鼠而非人类，NPY也存在于神经系统以外的血小板和内皮中(Zukovska-Grojec等，1993)。最初认为NPY是有效的血管收缩剂和神经调节剂。由于NPY在应激、运动、以及心肌缺血时释放，因此其被认为参与了冠心病、充血性心力衰竭、以及高血压的发病(Zukovska-Grojec等，1998)。由于近期发现NPY对食物摄取具有很强的刺激能力，因而猜测其在肥胖和糖尿病的发病中起了一定的作用(Kalra等，1999)。最近的研究提示NPY还是大鼠主动脉血管平滑肌细胞的一种有丝分裂原(Zukovska-Grojec等，1999)。
NPY相关性研究至少集中在三个主要方向：(1)共传递(co-transmission)和交感缩血管作用，这是由于其与去甲肾上腺素共表达；(2)CNS内的神经传递和功能，这是由于其强效的consummatory作用；以及(3)NPY的演化，这是由于NPY是已知的最为保守的生物活性肽之一(Colmers和Wahlestedt，1993：Lundberg，1996；Wahlestedt和Reis，1993；Wettstein等，1996)。NPY作用于至少6种受体(Y1-Y6)，具有不同的肽药理学并在CNS中具有截然不同的分布(Gehlert，1998)(表1)。NPY、NPY受体的亚型和mRNA的分布
NPY、NPY受体蛋白及其mRNA在人的CNS和大鼠脑内的分布最近已得到综述(Dumont Y，Jacques D，St-Pierre，J.-A，Tong，Y，Parker，R，Herzog H和Qurion，R，2000；化学神经解剖学手册，16卷：肽受体，部分I；Quirion，R，Bjorklund，A和Hkfeld，T，编者)。简要概括于表1。
含有NPY的神经元在包括人在内的多种动物的鼻粘膜有明显的分布，并通常与腺泡和血管相关联(Baraniuk等，1990；Grunditz等，1994)。对支配狗的鼻粘膜的副交感神经(翼管神经，vidian nerve)进行刺激可增加该区域的血流量，并主要引起阿托品抗性。静脉施用NPY可减少由于副交感神经刺激所引起的血管扩张，该作用不能被NPY Y1选择性激动剂[Leu31，Pro34]NPY所模拟，但可通过施用NPYY2受体激动剂N-乙酰[Leu28，Leu31]NPY(24-36)而模拟(Lacroix等，1994)。这与一种结合点前型(prejunctional)NPY Y2样受体所介导的对递质自副交感神经末端的释放的抑制作用相一致。NPY受体功能
NPY无疑是迄今为止所发现的最为丰富的神经肽，其在CNS和外周神经系统(PNS)具有广泛的分布。NPY与肽YY(PYY)(两者大约具有70％的同源性)和胰多肽(pancreatic polypeptide，PP)(两者大约具有50％的同源性)一同形成一种肽家族；NPY和PYY的生物活性尤其显著，而PP的活性通常弱的多(Gehlert，1998；Wahlestedt和Reis，1993)(表2)。
根据在体外分析系统中(Wahlestedt等，1986)与神经肽Y相比对一种截短的相关的肽YY-(13-36)的类似物的不同的反应性，将NPY的两种受体亚型称为神经肽Y Y1(结合点后型，postjunctional)和神经肽Y Y2(结合点前型，prejunctional)。神经元的结合点前型NPY受体的激活通常抑制神经活性，降低作为对神经冲动的应答和作为对促进神经递质释放的局部因子的应答的神经递质的释放(Wahlestedt等，1986)。所述结合点前型或神经肽Y Y2受体的分类是基于肽YY(13-36)的作用，但在多种系统中，该分子以及神经肽Y-(13-36)确实具有血管收缩活性(Rioux等，1986；Lundberg等，1988；Potter等，1989)。一些观点认为这代表一些血管床的结合点后膜具有两种类型的神经肽Y受体(神经肽YYj和神经肽Y2)(Schwartz等，1989)。而这些分子之所以缺乏选择性可能是因为其在Yj受体上保持了部分的激动剂活性，这使得它们引起了一种减弱了的功能性应答。以往曾描述了一种神经肽Y的13-36类似物(Leu 17，Glu＂，Ala21，Ala 22，Glu 23，LeU28，LeU31)，即神经肽Y-(13-36)(ANA神经肽Y-(13-36))，其在体内研究中具有相当于完整神经肽Y分子的结合点前活性(Potter等，1989)。
除却这些过去已经被详细说明的神经肽Y受体，药理学依据提示存在一些其他的亚型(Y3、Y4、Y5以及Y6)(Michel等，1998)，并且已经分别发表了克隆Y1、Y2、Y4和Y5受体的详细情况(Herzog等，1992；Gerald等，1995；Bard等，1995；Gerald等，1996)(表1)。这些不同的受体亚型的分布以及生理学意义还有待进一步确定。尽管对于神经肽Y的截短的形式对一种或另一种受体亚型的选择性一直存在争议(Potter等，1989)，但研究进展支持最初的结合点前和结合点后的受体亚型分类。已经建立了特异性表达一种神经肽Y受体亚型的细胞系，而具有受体选择性的神经肽Y类似物方面的进展主要集中于其在这些细胞系中的结合特征(Sheikh等，1989；Aakerlund等，1990；Fuhlendorff等，1990)。最近，一种编码神经肽Y Y1受体的cDNA已被克隆，而表达所述已被克隆的受体的细胞系已经被用于分析神经肽Y类似物的特异性结合(Herzog等，1992)以及由特异性类似物所引发的功能性应答。从这些有关结合性的研究中，并结合随后的体内研究，已有两种类似物被归类为可特异性作用于结合点后的神经肽Y Y1受体。这些具有神经肽YY受体选择性的类似物，(Pro34)神经肽Y和(Leu＂，Pro 34)神经肽Y，模拟了神经肽Y的升高血压的作用，并同样具有与仅表达神经肽Y Y受体的细胞系的结合，所述细胞系例如为表达克隆的神经肽Y Y受体的神经母细胞瘤细胞系SK-N-MC以及成纤维细胞系(Herzog等，1992)。两者均未显示出神经肽Y Y2受体作用即在体内抑制心脏迷走神经的作用，一种抑制乙酰胆碱释放的表现(Potter等，1991；Potter和McCloskey，1992)。
表1；NPY受体亚型在CNS内的分布和功能
| 受体亚型 | CNS表达 | 功能 | 选择性激动剂 | 选择性拮抗剂或选择性 |
| Y1 | 皮层，等 | 抗焦虑，LHRH释放 | 完整N端：[Leu31，Pro34]NPY | BIBP3226；BIBO 3304 |
| Y2 | 海马，下丘脑 | 抗遗忘 | C端末端：PYY3-36；PYY13-36 | T4[NPY(33-36)]4；BIIE0246 |
| Y3 | Ncl，TractusSolitarius(NTS) | 心动过缓，低血压 | NPY＞＞PYY，[Leu31，Pro34]NPY | PYY不敏感 |
| Y4 | 迷走神经背侧结(DVC) | 催吐 | PP＞＞NPY，PYY | PP优选 |
| Y5(a) | 下丘脑 | 喂食 | NPY，PYY，[Leu31，Pro34]NPY | [Leu31，Pro34]NPY敏感，BIBP3226不能逆转 |
| Y5(b)或Y6 | 下丘脑 | ？；种属特异性 | ？ | ？ |
| 表1：CNS内的NPY受体亚型；？＝未知或未研究 | ||||
具有高亲和性的、非肽类NPY拮抗剂BIBP3226和BIB03304的出现，十分有助于对NPY受体的功能性研究，这是由于该化合物对Y1R具有选择性，而至少对Y2R、Y3R和Y4R不具有活性(Doods等，1996)。近来报道了两种Y2受体拮抗剂。一种为TASP分子(Grouzmann等，1997)，另一种为非肽类拮抗剂(Wieland等，1999)，其他的非肽类的受体特异性化合物也已出现(Daniels等，1995)。因此，通过在脑内阻断特异性的受体，可以对由中枢性NPY受体介导的行为学和生理学效应进行功能性研究。此外，缺乏Y1R的小鼠也已经产生并可获得(Pedrazzini等，1998)。具有NPY样免疫反应性和NPY受体表达的神经元在CNS中含量丰富(表1)，且可能在下丘脑以及所谓的边缘结构(limbic structure)中最为明显，但其同样共定位于脑干单胺能性神经元(monoaminergic neuron)和皮质GABA能性神经元(GABA-ergic neuron)(Chronwall，1985；Dumont等，1996)。表2：受体亚型肽选择性
NPY，焦虑和抑郁
| 受体亚型 | 肽的效能 |
| Y1样Y1Y4Y6Y2样Y2Y5样Y5未克隆的PP受体Y3PYY优选 | NPY＝PYY＝Pro34-NPY＞PP＞NPY13-36PP＞＞NPY＝PYY＝LP-NPY＞NPY13-36NPY＝PYY＝Pro34-NPY＞NPY13-36＞PPNPY＝PYY＝NPY13-36＞Pro34-NPY＞PPNPY＝PYY＝Pro34-NPY＞NPY13-36＞PPPP＞＞PYY＝NPYNPY＝Pro34-NPY＝NPY13-36＞＞PYYPYY＞NPY＞＞NPY13-36＞＞Pro34-NPY |
| 表2：受体亚型肽选择性(根据1998年Gehlert)。 | |
NPY的抗焦虑样作用(anxiolytic-like effect)已通过使用elevatedplus maze test(Montgomery)、惩罚性饮水试验(punished drinking test，Vogel)、和惩罚性应答试验(punished responding test，Geller-Seifter)所证实，其效力和作用可与苯并二氮(benzodiazepine)相当(Griebel，1999；Heilig等，1989；Wettstein等，1995)。NPY在对新奇事物的应答(response to novelty)中发挥抗焦虑样作用(Heilig和Murison，1987；von B orsten等，1998b)，并在elevated plus maze和其他的焦虑相关性试验中产生抗焦虑样效应(Wahlstedt和Reis，1993；Wahlestedt等，1993)。有趣的是，经Y1受体的反义处理的大鼠(antisense-treated rat)表现出明显的焦虑相关性行为，但不出现运动和摄食的改变(Wahlestedt等，1993)。此外，在一种Flinder大鼠抑郁症模型上，Y1受体的mRNA表达在不同的皮质区域和海马齿状回(dentate gyrus of the hippocampus)是减低的，而Y2受体的mRNA表达与对照无区别(Caberlotto等，1998)。通过给大鼠进行嗅球切除术(Olfactory bulbectomy)建立了一种抑郁症模型(Leonard和Tuite，1981)。在该模型中出现的绝大多数的变化与抑郁症患者的症状相似(Song等，1996)。给切除嗅球的大鼠脑室内注射(i.c.v.)施用为期7天的NPY可减轻该动物模型的行为学和神经递质的缺陷(Song等，1996)。NPYY1、Y2、以及可能Y5受体似乎参与调节了啮齿动物的焦虑水平，其中Y1介导的效应被研究地最为深入(Heilig等，1993；Kask等，1998b)。因此可以认为，内源性NPY可对抗应激和焦虑(Heilig等，1994)。不仅如此，这些结果还提示Y1受体亚型可能参与了焦虑和抑郁相关性行为。此外，Kask等(1996)报道了脑室内注射Y1拮抗剂BIBP3226可在elevated plus-maze test中产生致焦虑样效应(anxiogenic-like effect)，但不出现任何运动异常。通过在背侧的导水管周边灰质(dorsal periaqueductal gray matter)施用BIBP3226也可产生此效应，但在篮斑(locus coeruleus)或视丘的脑室周边核施用却不能(Kask等，1998c)。此外，将BIBP3226和GR231118施用于背侧的导水管周边灰质，使大鼠的主动性社会交往减少(Kask等，1998d)。对于NPY发挥抗应激作用具有重要意义的脑部区域包括但不限于扁桃体(Sajdyk等，1999；Thorsell等，1999)，篮斑(Kask等，1998c)和背侧的导水管周边灰质(Kask等，1998a、b)。当用BIBP3226或BIB03304阻断NPY Y1R后，elevated plus-maze和社会交往试验并未发现焦虑加重，因此扁桃体NPY在低应激条件下并不释放(Kask等，1998b；Sajdyk，1999)。但是在背侧的导水管周边灰质似乎存在持续性NPY能性紧张度，在两个实验性焦虑模型中NPY Y1R拮抗剂均产生了致焦虑样效应(Kask等，1998a、b)。因此，在特定的脑部区域可能存在通过NPY系统对焦虑的紧张度调节。CNS NPY系统的神经学和精神生理学效应：多效性(pleiotropy)
因此，已有大量的研究致力于NPY及其同类物在CNS中的生理功能(见综述：Kalra和Crowley，1992；Dumont等，1992；Stanley，1993；Wahlestedt和Reis，1993；Grundemar等，1993；Gehlert，1994，1998；Colmers和Bleakman，1994；Wettstein等，1995；Heilig和Widerlow，1995；Munglani等，1996；Inui，1999；Bischoff和Michel，1999；Vezzani等，1999)并证明其具有广泛的效应。目前，尚未出现利用这些不同的生理功能的药理学方法。使用苯并二氮和NPY治疗焦虑相关性疾病在当前存在的问题
当前治疗焦虑的方法伴随若干问题：
被普遍用作抗焦虑药物的苯并二氮类属于低选择性或无选择性的非天然化合物。除了其抗焦虑活性，苯并二氮类还有镇静和抗癫痫的作用，并且还被认为可影响肌肉的放松。但是，其也伴有一些有害的不良反应，即疲劳、嗜睡、精力不集中、注意力和反应性下降。长期应用苯并二氮类会引起神经性疾病，例如共济失调、眩晕、腱反射丧失、肌肉和构音障碍。据推测使用苯并二氮类进行长期的治疗可致药物依赖和成瘾。
将直接脑室内注射施用神经肽Y作为焦虑症病人的长期治疗措施缺乏可行性。
发明内容
本发明的一个目的是提供一种有益于神经学和心理生理学效应的药物。本发明的一个特别的目的是提供一种吸诱素或吸诱素异构体的抑制剂以用于生产一种药物，所述药物可用于调节针对包括焦虑在内的应激而产生的行为和/或神经学适应性反应性。
此外，本发明的一个目的是通过提供一种药理学方法而克服或减少现有技术中存在的上述问题，并使哺乳动物脑内的NPY的活性和/或作用得以维持或延长。
这些目的是通过一种吸诱素或吸诱素异构体的抑制剂在生产一种用于调节针对包括焦虑在内的应激而产生的行为和/或神经学反应性的药物中的用途而解决的。
这导致由NPY Y1受体介导的内源性神经学或神经心理学效应增强，包括但不限于减轻焦虑、治疗被诊断为患有高血压、高血压病、发热、睡眠障碍、厌食症、包括抑郁症在内的焦虑相关性疾病、包括癫痫在内的抽搐、药物戒断和酗酒、包括认知障碍和痴呆在内的神经退行性疾病、以及包括精神分裂症在内的神经精神性疾病的对象。
图1所示为以DP IV和吸诱素(A)裂解处理RANTES 1-15和以吸诱素在无(左)和有(右)异亮氨酰噻唑烷半延胡索酸(isoleucyl-thiazolidine hemifumarate)(P32/98)存在的情况下裂解处理NPY的MALDI-TOF质谱图。
发明详述
与本领域中所提及的其他方法不同，本发明提供了一种低分子量的吸诱素或吸诱素异构体(同功酶)的抑制剂的口服治疗法。这一方便的发明代表了一种用于治疗哺乳动物的焦虑和其他神经学或心理学疾病的新途径。其使用方便，具有商业价值，并适合应用于治疗方案中，特别是对于人类疾病。
可口服的低分子量的吸诱素酶活性抑制剂例如为N-(N’-取代的氨基乙酰)-2-氰基吡咯烷，L-苏型-异亮氨酰噻唑烷，L-异-异亮氨酰噻唑烷(L-allo-isoleucyl thiazolidine)，L-苏型-异亮氨酰吡咯烷，L-异-异亮氨酰噻唑烷(L-allo-isoleucyl thiazolidine)，和L-异-异亮氨酰吡咯烷(L-allo isoleucyl pyrrolidine)。相关描述见US 6,001,155，WO99161431，WO 99/67278，WO 99/67279，DE 19834591，WO 97/40832，DE 19616486 C2，WO 98/19998，WO 00/07617，WO 99/38501，和WO 99/46272，其全文在此并入作为参考。
吸诱素是一种外肽酶(exopeptidase)，其选择性地在N端倒数第二的脯氨酸和丙氨酸残基后裂解肽链。目前已知有5种attactin的异构体。根据本发明，也可使用吸诱素样酶，对吸诱素样酶的选择可以通过例如下面的试验进行：对肽酶进行选择性在N端倒数第二的脯氨酸和丙氨酸残基后裂解肽的试验，选择出能够实现此裂解的肽酶并分离该肽酶。
吸诱素抑制剂的多种作用提示，当其被用于治疗发生病理变化的组织时，其会对正常健康组织和器官产生影响。本发明的目标是开发具有高选择性的、定向于脑的、吸诱素和吸诱素异构体抑制剂，其具有很高的生物利用度和靶组织内的可精确预测的活性时间。
可口服的低分子量药剂的例子为吸诱素酶活性的稳定和不稳定的抑制剂的前体药物(prodrug)，其包含通式A-B-C，其中A代表一种氨基酸，B代表A和C之间的化学键或者一种氨基酸，而C代表一种吸诱素酶活性的不稳定或稳定的抑制剂。见WO 99/67278，WO99/67279所述，其全文在此并入作方参考。
本发明涉及一种新型的治疗方法，其中由吸诱素酶的效应分子(effector)所引起的哺乳动物脑内的吸诱素酶或吸诱素异构体的活性的下降，由此而产生的结果是神经肽Y(NPY)的降解减少。该治疗可导致具有功能活性的NPY(1-36)的浓度的下降出现减少或延迟。
根据本发明可以看出，哺乳动物、特别是人的脑内的NPY的效应和/或活性可通过施用吸诱素或吸诱素异构体(同功酶)的抑制剂而得以维持或延长。由此可减少脑内NPY的降解。这可减轻或改善心身性、抑郁性和/或神经精神性疾病。这一方便的发明特别代表了一种治疗焦虑症以及其他神经学或心理学疾病的新型方法。其使用方便，具有商业价值，并适合应用于治疗方案中，特别是对于人类疾病。
令人惊异地，本发明人发现，施用吸诱素抑制剂异亮氨酰噻唑烷显示出抗焦虑效应。
吸诱素及其异构体存在并广泛分布于大鼠的脑中(Lu等，1999)。本发明人在实施例1中显示，NPY在体外是吸诱素的主要底物。
作为吸诱素活性被抑制而引起的内源性NPY(1-36)稳定性增加的结果，NPY的活性被延长，这导致具有功能活性的NPY Y1受体活性，而后者有益于抗抑郁、抗焦虑和抗高血压效应等(见上)。
本发明的用于治疗动物包括人的焦虑症的方法包含通过抑制吸诱素或吸诱素异构体而强化NPY的效应。在大多数情况下，吸诱素抑制剂可优选地通过口服施用。通过抑制吸诱素酶的活性，使活化形式的NPY的半衰期在生理条件下得以延长和维持。而延长存在的活化NPY可增强NPY Y1受体的活性。
本发明还提供了药物组合物，所述组合物包含一种治疗(或预防)有效量的所述抑制剂(和/或与吸诱素抑制剂一同施用的糖丸)，以及一种药用可接受的载体或赋形剂，其特别适合于定向于脑。合适的载体包括但不限于盐、缓冲盐、葡萄糖、水、甘油、乙醇、及其组合。所述载体和组合物优选地在良好的实验操作条件下进行，且最优选为无菌条件下。配方的选择在理论上要适合于施用方式，符合常规的操作。
适合的药用可接受的载体包括但不限于水、盐溶液(如NaCl)，酒精、阿拉伯树胶、植物油、苯甲醇(benzyl alcohols)、聚乙二醇、凝胶、碳水化合物例如乳糖、直链淀粉或淀粉、硬脂酸镁盐、滑石粉、粘性石蜡、芳香油、脂肪酸酯、羟甲基纤维素、和聚乙烯吡咯烷酮等。所述药用制剂可进行无菌处理，并在需要时混合入辅助剂，例如润滑剂、防腐剂、稳定剂、湿润剂、乳化剂、用于影响渗透压的盐、缓冲剂、着色剂、调味剂和/或芳香物质等等，其不应与所述活性化合物发生有害反应，但可改善其稳定性、可加工性和/或外观美感。
如果需要，所述组合物可以含有少量的湿润剂或乳化剂，或者pH缓冲剂。此外，所述组合物可以是液体溶液、悬浊液、乳液、片剂、丸剂、胶囊、控释剂型、或粉剂。此外，所述组合物可以通过传统的结合剂和载体如甘油三酯而配制成栓剂。口服配方可以包括标准的载体例如药用等级的甘露醇、乳糖、淀粉、硬脂酸镁盐、聚乙烯吡咯烷酮、糖精钠、纤维素、碳酸镁等。
进一步，所述组合物可根据常规程序配制为适合于给人静脉施用的药用组合物。有代表性地，静脉施用的组合物为无菌等渗缓冲溶液。必要时，所述组合物也可以包括溶剂以及局部麻醉剂，以减轻注射部位的疼痛。通常，所述成分可以单独形式提供或混合成单位剂型，例如密封容器内的冻干粉剂或无水浓缩物，所述容器例如为标明活性化合物量的安瓿或药囊(sachette)。若所述组合物以输液方式施用，其可以被置于含有无菌药用级水、盐或葡萄糖/水的输液瓶中。若所述组合物以注射方式施用，可提供一安瓿注射用水或盐水以便在施用前将所述成分进行混合。
最后，本发明的组合物可配制成中性或盐的形式。药用可接受的盐包括与游离氨基反应形成的盐，如衍生自盐酸、磷酸、乙酸、草酸、酒石酸等的盐，以及衍生自钠、钾、铵、钙、氢氧化铁、异丙胺、三乙胺、2-乙氨基乙醇、组胺、普鲁卡因等的盐。
用于治疗一种特定的疾病或病情的本发明的组合物的有效剂量取决于所述疾病或病情的性质，并可通过标准的临床技术加以确定。此外，可任选地通过体外和/或体内分析来确定最佳剂量的范围。配方中所用的确切剂量还将取决于施用途径、疾病的严重程度，并应根据医疗人员的判断和每个病人的具体情况而决定。
本领域人员应明白，对本发明在此给出的实施例和指导进行的各种改动，包括产生不同的吸诱素抑制剂和替代性治疗组合物，均未脱离本发明的精神和范围。
下面将结合实施例对本发明做进一步阐述，重点在于通过抑制吸诱素活性而产生的抗焦虑样和应激保护性样的作用。
实施例
实施例1
在体外，NPY是人吸诱素的一种底物
来自人血浆的吸诱素制备于取自健康人的100ml血浆(BaxterGmbH Germany，Plasmazentrum Halle)。使用惠普(Hewlett-Packard)G2025 LD-TOF系统来进行基质辅助的激光解离/离子化质谱(Matrix-assisted laser desorption/ionisation mass spectrometry)。
在有或无异亮氨酰噻唑烷(10μM)存在的情况下，用纯化的DP IV和吸诱素处理以获得肽(25μM)的质谱，为此，将底物与40mM tricine/HCI缓冲液(pH7.6)和酶溶液以2∶2∶1的比例在37℃温育。在不同的时间间隔将反应混合物的样品取出并与等量的基质溶液混合。通过将样品和基质进行混合分析，基质溶液的低pH值使得酶反应停止。将少量的此基质溶液转移至探针顶端并在惠普G2024A样品处理器(Hewlett-Packard G2024A Sample Prep Accessory)中立即蒸发。
吸诱素的蛋白裂解活性被进一步加以研究。经测定，Gly-Pro-pNA的Km值为0.14mM，与DP IV、吸诱素和一种血清DP IV样活性的值相当。此外还分析了诸如NP Y、RANTES、GIP、和胰高血糖素(Glucagon)等生物活性肽被纯化的吸诱素所裂解。类似于DP IV，吸诱素能够使NPY的N端的二肽Tyr-Pro释放(图1B，左)。当存在异亮氨酰噻唑烷时，裂解被抑制(图1B，右)。此前，曾报道了趋化因子(chemokine)RANTES被DP IV和吸诱素水解存在不同之处4。但是，我们的结果没有证实这些数据。与DP IV相似(图1A，左)，纯化的吸诱素能够自合成的RANTES1-15的N端相继释放第一个(Ser-Pro)和第二个(Tyr-Ser)二肽(图1A，右)。
参考文献Aakerlund，L.，U.Gether，T.W.Schwartz，和O.Thastrup(1990)，神经肽Y的Yj受体偶联于细胞内钙的固定Agmo，A和Belzung，C，多巴胺和GABA的相互作用在控制小鼠的运动活性和新奇恐怖症中的作用，Pharmacol.Biochenz.Bellav，59(1998)239-247.Agmo，A和Belzung，C，阿片类受体的亚型在利眠宁的抗焦虑作用中的作用，Neuropharmacology，37(1998)223-232.Agmo，A，Galvan，A，Heredia，A和Morales，M，纳洛酮阻断苯并二氮和戊巴比妥的抗焦虑作用但不阻断其运动作用：实验研究及文献综述，Psychopharmacology Berl，120(1995)186-194.Arvat，E，Maccagno，B，Ramunni，J，Di-Vito，L，Gianotti，L，Broglio，F，Benso，A，Deghenghi，R，Camanni，F和Ghigo，E，地塞米松和阿普唑仑(一种苯并二氮)在人类对hexarelin(一种合成的GHRP)的ACTH、皮质醇和GH的促释放作用的影响，Neuroendocrinology，67(1998)310-316.Band，L.C，Pert，A，Williams，W，De Costa，B.R，Rice，K.C和Weber，R.J，中枢性μ阿片类受体在体内介导对自然杀伤活性的抑制，Prog.Neuro.Endocrinol.Immunol，5(1992)95-101.Baram，T.Z，Yi，S，Avishai，E.S和Schultz，L，应激应答的发育神经学：促肾上腺皮质激素释放激素功能的多层次调节，Ann.N.Y.Acad.Sci，814(1997)252-265.Baraniuk，J.N，Castellino，S，Lundgren，J.D，Goff，J，Mullol，J，Merida，M，Shelhamer，J，H和Ka liner，M.A.(1990)，人类鼻粘膜的神经肽Y(NPY).J.Respir.Cell Mol.Biol.3，165-173.Bard，J.A，Walker，M.W，Branchek，T.A和Weinshank，R.L.(1995)，J.Biol.Chem，270，26762-26765.胰多肽、神经肽Y和肽YY受体亚型Y4的克隆和功能表达.Berkenbosch，F，van-Oers，J，del-Rey，A，Tilders，F和Besedovsky，H，大鼠的由白细胞介素1激活的产生促肾上腺皮质激素释放因子的神经元，Science，238(1987)524-526.Bertolucci，M，Perego，C和De Simoni，M.G，大鼠中枢性阿片制剂对外周IL-6的调节，NeuroReport，7(1996)1181-1184.Bertolucci，M，Perego，C和de Simoni，M.G，IL-6受中枢性阿片类受体亚型的不同调节，Am.J.Pllysiol，273(1997)R956-R959.Bileviciute，I，Stenfors，C，Theodorsson，E，Beckman，M和Lundeberg，T，正常血压大鼠(WKY)和自发性高血压大鼠(SHR)继发于膝关节单关节炎的脑内神经肽浓度的显著改变，Brain Res，704(1995)71-78.Britton，D.R，Koob，G F，Rivier，J和Vale，W，脑室内的促肾上腺皮质激素释放因子增强新奇事物的行为学效应，Life Sci，31(1982)363-367.Britton，K.T，Lee，G和Koob，G.F，促肾上腺皮质激素释放因子和安非他明放大苯并二氮拮抗剂Ro 15-1788在冲突试验中的部分激动剂特性，PsycllopSlarmacology Berl，94(1988)306-311.Brown，M.R，Fisher，L.A，Spiess，J，Rivier，J，Rivier，C和Vale，W，促肾上腺皮质激素释放因子和sauvagine的生物学作用的比较，RegZzl.Pept，4(1982)107-114.Calenco，C.G，Dauge，V，Gacel，G，Feger，J和Roques，B.P，在大鼠腹面大脑脚盖区域注射阿片类δ激动剂和内源性脑啡肽诱导出与注射μ激动剂不同的情绪反应，Psychopharrnacoloy Berl，103(1991)493-502.Carr，D.J，Rogers，T.J和Weber，R.J，阿片类和阿片类受体在免疫活性和免疫内稳态上的相关性，Proc.Soc.Erp.Biol.Afed，213(1996)248-257.Chen，C，Dagnino，R，De-Souza，E.B，Grigoriadis，D.E，Huang，C.Q，Kim，K.I，Liu，Z，Moran，T，Webb，T.R，Whitten，J.P，Xie，Y.F和McCarthy，J.R，设计并合成一系列非肽类高亲和性人促肾上腺皮质激素释放因子拮抗剂，J.Aled.Chers，39(1996)4358-4360.Chronwall，B.M，神经内分泌弓形核的解剖学核生理学，Peptides，6Suppl 2(1985)1-11.Colmers，W和Wahlestedt，C.(1993)神经肽Y和相关的肽类的生物学.Humana Press，Totowa，New Jersey.Conte，D.B，Rey，M，Boudouresque，F，Giraud，P，Castanas，E，Millet，Y，Codaccioni，J.L.和Oliver，C，41-CRF抗血清对大鼠ACTH、B-内啡肽和α-MSH的分泌的影响，Peptides，4(1983)301-304.Daniels，A.J，Matthews，J.E，Slepetis，R.J，Jansen，M，Viveros，O.H，Tadepalli，A，Harrington，W，Heyer，D，Landavazo，A，Leban，J.J等，高亲和性神经肽Y受体拮抗剂，Proc.Natl.Acad.Sci.U.S.A，92(1995)9067-9071.Devine，D.P，Taylor，L，Reinscheid，R.K，Monsma-FJ，J，Civelli，O和Akil，H，大鼠对新的神经肽orphanin FQ的运动抑制效应出现快速的耐受，Neurochem.Res，21(1996)1387-1396.Dieterich，K.D，Lehnert，H和De-Souza，E.B，促肾上腺皮质激素释放因子受体：概述，E.rp.Clin.Endocnnol.Diabetes，105(1997)65-82.Doods，H.N，Wieland，H.A，Engel，W，Eberlein，W，Willim，K.D，Entzeroth，M，Wienen，W.和Rudolf，K，BIBP 3226，第一个神经肽Y1受体拮抗剂：药理学特性的综述，Regul，Pept，65(1996)71-77.Duke-Cohan JS，Morimoto C，Rocker JA，Schlossman SF：血清高分子量二肽肽酶IV(CD26)与一种由激活的T细胞释放的新型抗原DPPT-L相似，The joumal of immunology 156，1714-21(1996)Duke-Cohan JS，Tang W，Schlossman SF：吸诱素：一类参与T细胞与单核/巨噬细胞相互作用的新型蛋白酶，Adv.Exp.Me d.Biol.477，173-185(2000)Dumont，Y，Foumier，A，St，P.S和Quirion，R，用2种新研制的Y1和Y2受体的放射性标记的配体评价大鼠脑内[125I]Leu31，Pro34]PYY和[125I]PYY3-36结合位点的放射自显影分布，Synapse，22(1996)139-158.Dunn，A.J，Berridge，C.W，Lai，Y.I和Yachabach，T.L，CRF诱导的大鼠和小鼠的过度自洁行为，Peptides，8(1987)841-844.Egawa，M，Yoshimatsu，H和Bray，G.A，神经肽Y抑制大鼠肩胛间棕色脂肪组织的交感神经活性，Am.J.Physiol，260(1991)R328-R334Eghbal，A.M，Hatalski，C.G，Avishai，E.S和Baram，T.Z，新生大鼠下丘脑腹正中核的促肾上腺皮质激素释放因子受体II(CRF2)的mRNA水平可因失去母亲而降低，Endocrinology，138(1997)5048-5051.Ekman，R，Servenius，B，Castro，M.G，Lowry，P J，Cederlund，A.S，Bergman，O和Sjogren，H.O，人类T淋巴细胞内促肾上腺皮质激素释放激素的生物合成，J.Neuroimmirnol，44(1993)7-13.File，S.E，行为学研究对于焦虑症的神经药理学的贡献，Nelaropharmacology，26(1987)877-886.Florin，S，Suaudeau，C，Meunier，J.C和Costentin，J，Nociceptin刺激小鼠的运动和探险行为，Eur.J.Pharmacol，317(1996)9-13.Fuhlendorff，J，U.Gether，L.Aakerlund，N.Langeland-Johansen，H.Togerson，S.GF.Melberg，U.B.Olsen，O.Thastrup，和T.W.Schwartz3134(1990)，[LeU，Pro]神经肽Y：一种特异性Yj受体激动剂，Proc.Natl.Acad.Sci.87，182-186.Gaveriaux，R.C，Matthes，H.W，Peluso，J和Kieffer，B.L，去除吗啡在缺乏μ阿片类受体基因的小鼠的免疫抑制作用，Proc.Natl.Acad.Sci.U.S.A，95(1998)6326-6330.Gehlert，D.R，胰多肽(PP-fold)家族的多样性受体：生理学意义，Proc.Soc.Exp.Bio1.Med，218(1998)7-22.Gerald，C，Walker，M，W，Criscione，L，Gustafson，E.L，Batzi-Hartmann，C，Srmith，K.E＂Vaysse，P，Durkin，M.M，Laz.T.M，Linemeyer，D.L，Schaffhauser，A.O，Whitebread，S，Hofbauer，K.G，Taber，R.I，Branchek，T，A和Weinshank，R.L.(1996).一种受体亚型参与神经肽Y诱导的摄食.Nature，382，168-171.Gerald，C，Walker，M.W，Vaysse，P.J.-J，He，C，Branchek，T.A和Weinshank，R.L.(1995)J.Biol.Chem，270，26758-26761.人类海马神经肽N＇/肽N＇Y Y2受体亚型的表达克隆和药理学特征.Gosnell，B.A，Levine，A.S和Morley，J.E，μ、κ和δ阿片类受体的选择性激动剂刺激摄食，Life Sci，38(1986)1081-1088.Grosskreutz，C.L和Brody，M.J，中枢施用促肾上腺皮质激素释放因子(CRF)引起的局部血液动力学反应，Brain Res，442(1988)363-367.Grouzmann，E，Buclin，T，Martire，M，Cannizzaro，C，Domer，B，Razaname，A和Mutter，M，神经肽Y的Y2受体的选择性拮抗剂的特征：一种Y2拮抗剂的合成和药理学评价，J.Biol.Chem，272(1997)7699-7706.Grundemar，L，Grundstrom，N，joahansson，1.G.M，Andersson，R.G.G和Hakanson，R.(1990)神经肽Y对辣椒素敏感性感觉神经介导的豚鼠气道收缩的抑制作用.Br.J.Pharmacol，99，473-476.Grundemar，L，Wahlestedt，C和Wang，Z.Y.(1993)神经肽Y抑制兔眼的神经性炎症反应；作用方式.Regul.Pept，43，57-64.Grunditz，T，Uddman，R和Sundler，F.(1994)大鼠鼻粘膜神经纤维的起源和肽含量.Anat.Embryo.189，327-337.Gue，M，Junien，J.L，Reeve-JR，J，Rivier，J，Grandt，D和Tache，Y，NPY、PYY和NPY和PYY的3-36分子形式去除脑池CRF诱导对的大鼠胃酸分泌的抑制，Br.J.Pharmacol，118(1996)237-242.Heilig，M和Murison，R，脑室内的神经肽Y抑制大鼠在开阔地带和笼中的活动，Regul.Pept，19(1987)221-231.Heilig，M，B.Sderpalm，J.A.Engel和E.Widerlv，(1989)，中枢性施用神经肽Y(NPY)在焦虑动物模型中产生抗焦虑样效应，Psychopharmacology，98，524-529.Heilig，M，McLeod，S，Brot，M，Heinrichs，S.C，Menzaghi，F，Koob，G.F和Britton，K.T，神经肽Y的抗焦虑样作用：由扁桃体内的Y1受体介导，并与摄食效应解离，Neuropsychophannacology，8(1993)357-363。Heilig，M，Soderpalm，B，Engel，J.A和Widerlov，E，中枢性施用神经肽Y(NPY)在焦虑动物模型中产生抗焦虑样效应，Psychopharmacology Berl，98(1989)524-529.Heinrichs，S.C，Lapsansky，J，Behan，D.P，Chan，RK，Sawchenko，P.E，Lorang，M，Ling，N，Vale，W.W和De-Souza，E.B，促肾上腺皮质激素释放因子结合蛋白配体抑制剂减轻遗传性肥胖Zucker大鼠和尼古丁戒断大鼠的体重过度增加，Proc.Natl.Acad.Sci.U.S.A，93(1996)15475-15480.Heinrichs，S.C，Pich，E.M，Miczek，K.A，Britton，K.T和Koob，G.F，促肾上腺皮质激素释放因子拮抗剂通过直接的亲神经作用减轻社交挫折大鼠的情绪反应，Brain Res，581(1992)190-197.Herz，A，阿片类奖赏机制：在毒品使用的关键作用？Can.J.Physiol.Pharmacol，76(1998)252-258.Herzog，H，Y.J.Hort，H.J.Ball，G.Hayes，J.Shine，and L.A.Selbie(1992)，克隆的人神经肽Y受体偶联于2种不同的第二信使系统，Proc.Natl.Acad.Sci.U.S.A.89，5794-5798.Hoehe，M和Duka，T，阿片类增加人血浆中的儿茶酚胺，Psychoneuroendocrinologoy，18(1993)141-148.Hoffman，K.E，Maslonek，K.A，Dykstra，L.A和Lysle，D.T，中枢施用吗啡对Lewis和Wistar大鼠免疫状态的影响.In B.M.Sharp，T.K.Eisenstein，J.J.Madden和H.Friedman(Eds.)脑的免疫轴和物质滥用，Plenum Press，New York，1995，pp.155-159.Horvath，T.L，Naftolin，F，Kalra，S.P和Leranth，C，神经肽-Y支配大鼠下丘脑中基含有β内啡肽的细胞：光镜和电镜双重免疫染色分析[published erratum appears in Endocrinology 1996 Feb；137(2)：532]，En-docrivoloy，131(1992)2461-2467.Jankovic，B.D和Radulovic，J，Enkephalins，脑和免疫性：通过将甲硫氨酸-脑啡肽注入脑室而调节免疫反应，Int.J.Neurosci，67(1992)241-270.Jcnck，F，Moreau，J.L，Martin，J.R，Kilpatrick，G.J，Reinscheid，R.K，Monsma-FJ，J，Nothacker，H.P和Civelli，O，Orphanin FQ发挥抗焦虑作用以减轻针对应激的行为学反应，Proc.Natl.Acad.Sci.C/.S.X，94(1997)14854-14858.Kalra，P.S，Norlin，M和Kalra，S.P，神经肽Y刺激视丘下部β内啡肽的释放：性激素的作用，Brain Res，705(1995)353-356.Karalis，K，Muglia，L.J，Bae，D，Hilderbrand，H和Majzoub，J.A，CRH和免疫系统，J.Nettroimmunol，72(1997)131-136.Kask，A，L.Rgo和J.Harro，(1998)，背侧导水管周边灰质的NPYY1受体调节社交活动中的焦虑症，Neuroreport，9，2713-2716.Kask，A，Rago，L和Harro，J，在大鼠的篮斑附近微注射神经肽Y(NPY)和NPY 13-36抗焦虑效应，Brain Res，788(1998)345-348.Kiritsy，R.J，Appel，N.M，Bobbitt，F.G和Van-Loon，G.R，刺激下丘脑脑室周边核的μ阿片类受体对基础和应激诱导的儿茶酚胺释放以及心血管反应的效应，J.Pharmacol.E.rp.Ther，239(1986)814-822.Kiritsy，R.J，Marson，L和Van-Loon，G.R，对高选择性μ和δ阿片类肽的交感肾上腺、心血管和血气反应，J.Phannacol.Exp.The：，251(1989)1096-1103.Konig，M，Zimmer，A.M，Steiner，H，Holmes，P.V，Crawley，J.N，Brownstein，M.J和Zimmer，A，缺乏前脑啡肽的小鼠的疼痛反应、焦虑和进攻性，Nature，383(1996)535-538.Koob，G.F和Bloom，F.E，促肾上腺皮质激素释放因子和行为，Fed.Proc，44(1985)259-263.Kotz，C.M，Grace，M.K，Billington，C.J和Levine，A.S，norbinaltorphimine、beta funaltrexamine和naltrindole对NPY诱导的喂食的影响，Brain Res，631(1993)325-328.Krepela E，Kraml J，Vicar J，Kadlecova L，Kasafirek E：二肽肽酶IV水解抑胃肽、胰高血糖素样肽1(7-36)氨基化合物、PeptideHistidine Methionin并负责其在人类血清中的降解，Eur.J.Biochem.214，829-835(1993)Lacroix，J.S，Ulman，L.G和Potter，E.K.(1994)神经肽Y通过结合点前Y2受体对副交感神经引发的鼻血管收缩的调节.Br.J.Pharmacol，113，479-484.Lambert，P.D，Wilding，J.P，al-Dokhayel，A.A，Gilbey，S.G和Bloom，S.R，中枢性阻断κ阿片类受体对神经肽Y诱导的大鼠的喂食的影响，Brain Res，629(1993)146-148.Leu，S.J和Singh，V.K，促肾上腺皮质激素释放神经激素对天然杀伤细胞介导的细胞裂解的调节，J.Neuroimmunol，33(1991)253-260.Levine，A.S和Billington，C.J，阿片类，喂食的调节因子？Ann.N.Y.Acad.Sci，575(1989)209-219.Locke，K.W和Holtzman，S.G，μ或δ受体选择性阿片类肽的行为学效应.I.吗啡样区别性刺激效应，J.Pharmacol.Exp.Ther，238(1986)990-996.Loh，H.H，Liu，H.C，Cavalli，Ab，Yang，W，Chen，Y.F和Wei，L.N，敲除小鼠的μ阿片类受体：对配体诱导的痛觉丧失和吗啡致命性的影响，Brain Res.Mol.Brain Res，54(1998)321-326.Lu，X.-Y，Gunn，T.M，Shieh，K.-R，Barsh，G.S，Akil，H，Watson，S.J，Mahogany/吸诱素的mRNA在大鼠中枢神经系统的分布.FEBSLetters 462(1999)，101-107.Lundberg，J.M，自主神经系统内共传递药理学：胺、神经肽、ATP、氨基酸和NO的整合，Pharmacol.Rev，48(1996)113-178.Lundberg，J.M，Hensen，A，Larsson，0，Rudehill，A，Saria，A &Fredholm B.B，(1988)。猪脾脏内的神经肽Y受体：结合特征、减少cAMP的形成以及钙拮抗剂对血管收缩的抑制.Eur J.Pharmacol.Vol.45；21-29Lysle，D.T，Hoffman，K.E和Dykstra，L.A，导水管周边灰质尾部区域参与了吗啡诱导的免疫状态改变的一类亚型的证据，J.Pharmacol.E.rp.Tiller，277(1996)1533-1540.Makino，S，Takemura，T，Asaba，K，Nishiyama，M，Takao，T和Hashimoto，K，大鼠下丘脑脑室周边核的1型和2型α促肾上腺皮质激素释放神经激素受体mRNA的不同调节，Brain Res.AIol.BrainRes，47(1997)170-176.Mamiya，T，Noda，Y，Nishi，M，Takeshima，H和Nabeshima，T，nociceptin/orphanin FQ受体敲除小鼠的空间注意力增强，Brain Res，783(1998)236-240.Manabe，T，Noda，Y，Mamiya，T，Katagiri，H，Houtani，T，Nishi，M，Noda，T，Takahashi，T，Sugi moto，T，Nabeshima，T和Takeshima，H，助长缺乏nociceptin受体的小鼠的长期能力和记忆力，Nature，394(1998)577-581.Matthes，H.W，Maldonado，R，Simonin，F，Valverde，O，Slowe，S，Kitchen，I，Befort，K，Dierich，A，Le-Meur，M，Dolle，P，Tzavara，E，Hanoune，J，Roques，B.P和Kieffer，B.L，缺乏μ阿片类受体基因的小鼠丧失吗啡诱导的痛觉丧失、奖赏效应和戒断症状[see comments]，Nature，383(1996)819-823.May，C.N，Dashwood，M.R，Whitehead，C.J和Mathias，C.J，给清醒的兔子中枢性施用选择性阿片类激动剂诱发不同的心血管和呼吸反应：与受体分布相关，Br.J.Pharitiacol，98(1989)903-913.Mellado，M.L，Gibert，R.J，Chover，A.J和Mico，J.A，给小鼠脑室内施用低剂量神经肽Y对nociception的影响，Life Sci，58(1996)2409-2414.Mellon，R.D和Bayer，B.M，中枢阿片类受体参与吗啡的免疫调节作用的依据：潜在作用机制的综述，J.Neuroimmunol，83(1998)19-28.Mellon，R.D和Bayer，B.M，中枢性阿片类受体亚型在吗啡诱导的外周淋巴细胞活性改变中的作用，Brain Res，789(1998)56-67.Menzaghi，F，Heinrichs，S.C，Pich，E.M，Tilders，F.J和Koob，G.F，免疫靶向毒素引起的下丘脑促肾上腺皮质激素释放因子神经元的功能损害增强神经肽Y诱导的摄食，Brain Res，618(1993)76-82.Menzaghi，F，Howard，R.L，Heinrichs，S.C，Vale，W，Rivier，J和Koob，G.F，新的和有效的大鼠促肾上腺皮质激素释放因子拮抗剂的特征，J.Pharmacol.Exp.Ther，269(1994)564-572.Mercer，M.E和Holder，M.D，食物渴望、内源性阿片肽和摄食：综述，Appetite，29(1997)325-352.Meunier，J.C，Mollereau，C，Toll，L，Suaudeau，C，Moisand，C，Alvinerie，P，Butour，J.L，Guillemot，J.C，Ferrara，P，Monsarrat，B等，阿片类受体样ORL 1受体内源性激动剂的分离和结构[seecomments]，Nature，377(1995)532-535.Millan，M.J，κ阿片类受体和痛觉丧失，Trends.Pharmacol.Sci，11(1990)70-76.Minami，M和Satoh，M，阿片类受体的分子生物学：结构、功能和分布，Neurosci.Res，23(1995)121-145.Mogil，J.S，Grisel，J.E，Reinscheid，R.K，Civelli，O，Belknap，J.K和Grandy，D.K，Orphanin FQ是一种功能性抗阿片肽，Neuroscience，75(1996)333-337.Mollereau，C，Parmentier，M，Mailleux，P，Butour，J.L，Moisand，C，Chalon，P，Caput，D，Vassart，G和Meunier，J.C，ORL 1，阿片类受体家族的新成员.克隆、功能表达和定位研究，FEBS Lett，341(1994)33-38.Motta，V和Brandao，M.L，背侧导水管周边灰质的吗啡在接受elevated plus-maze test的大鼠引起的厌恶和反厌恶效应，Pharmacol.Biochem.Behav，44(1993)119-125.Nassel，Dr，Mentlein，R，Bollner，T，Karlsson，A，蟑螂脑和肠道内的脯氨酸特异性二肽肽酶的活性：部分特征、分布以及速激肽相关性肽的灭活，J Comp Neurol，418(2000)81-92Nishi，M，Houtani，T，Noda，Y，Mamiya，T，Sato，K，Doi，T，Kuno，J，Takeshima，H，Nukada，T，Nabeshima，T，Yamashita，T，Noda，T和Sugimoto，T，缺乏nociceptinlorphanin FQ受体的小鼠的无限制性伤害感受应答和听力失调，EAIBO J，16(1997)1858-1864.Noble，F，Smadja，C，Valverde，O，Maldonado，R，Coric，P，Turcaud，S，Fournie，Z.M和Roques，B.P，第一种口服活性脑啡肽代谢酶抑制剂RB 120对各种伤害性刺激(热、化学、电和炎症)的疼痛抑制效应，Pain，73(1997)383-391.Noda，Y，Mamiya，T，Nabeshima，T，Nishi，M，Higashioka，M和Takeshima，I-I，在nociceptin受体敲除小鼠中纳络酮benzoylhydrazone诱导的镇痛作用丧失，J.Biol.Chez，273(1998)18047-18051.Novak，J.E，Gomez-Flores，R，Calderon，S.N，Rice，K.C和Weber，R.J，脑室内注射SNC80后大鼠的天然杀伤细胞、T细胞和巨噬细胞的功能，J.Pharmacol.Exp.Ther，286(1998)931-937.Olson，G.A，Olson，R.D和Kastin，A.J，内源性阿片，1995，Peptides，17(1996)1421-1466.Ono，N，Lumpkm，M.D，Samson，W.K，McDonald，J.K和McCann，S.M，抑制大鼠的生长激素和LH释放的促肾上腺皮质激素释放因子(CRF)的下丘脑内作用，Life Sci，35(1984)1117-1123.Pechnick，R.N，阿片类对下丘脑-垂体-肾上腺轴的影响，Arittu.Rev.Pharmacol.Toxicol，33(1993)353-382.Pedrazzini，T，Seydoux，J，Kunstner，P，Aubert，J.F，Grouzmann，E，Beermann，F和Brunner，H.R，缺乏NPY Y1受体的小鼠的心血管反应、喂食行为和运动活性[see comments]，Nat.Bled，4(1998)722-726.Pfeiffer，A，Brantl，V，Herz，A和Emrich，H.M，κ阿片类受体介导的拟精神病，Science，233(1986)774-776.Pomonis，J.D，Billington，C.J和Levine，A.S，Orphanin FQ，孤儿阿片类受体ORL1的激动剂，刺激大鼠的喂食，Neuroreport，8(1996)369-371.Potter，E.K和M.J，D.McCloskey，(1992)，[Leu 3＇，Leu 341神经肽Y，麻醉大鼠内的神经肽Y受体的一种45选择性功能激动剂，Neurosci.Lett.134，183-186.Potter，EX，J.Fuhlendorff和T.W.Schwartz(1991)，[Pro34 J神经肽Y在大鼠和狗体内选择性识别神经肽Y的结合点后介导的作用，Eur.J.Pharmacol.193，15-19.Potter，EX，Mitchell，L，McCloskey，M.J，Tseng，A，Goodman，A.E，Shine，J和McCloskey，D.I.(1989)神经肽Y和相关性肽类的结合点前和结合点后作用.Regul.Pept.25，167-177.Privette，T.H和Terrian，D.M，κ阿片类激动剂在elevated plus-maze产生抗焦虑样行为，Psychopharmacology Berl，118(1995)444-450.Radulovic，J和Jankovic，B.D，脑内阿片类受体在调节大鼠的体液和细胞介导的免疫应答中的相反活性，Brain Res，661(1994)189-195.Radulovic，J，Miljevic，C，Djergovic，D，Vujic，V，Antic，J，von-Horsten，S和Jankovic，B.D，阿片类受体在体内和体外介导的体液免疫应答的抑制：涉及κ阿片类受体，J.Neuroimmunol，57(1995)55-62.Rassnick，S，Heinrichs，S.C，Britton，K.T和Koob，G.F，在扁桃体中央核内微注射促肾上腺皮质激素释放因子拮抗剂逆转酒精戒断的致焦虑样作用，Brain Res，605(1993)25-32.Reinscheid，R.K，Nothacker，H.P，Bourson，A，Ardati，A，Henningsen，R.A，Bunzow，J.R，Grandy，D.K，Langen，H，Monsma-FJ，J和Civelli，O，Orphanin FQ：一种激活阿片样G蛋白偶联受体的神经肽，Science，270(1995)792-794.Rioux，F，H.Bachelard，J.C.Martel和S.St.-Piere，(1986)，神经肽Y和相关性肽在豚鼠离体心脏的血管收缩剂效应，Peptides，7，27-31.Risdahl，J.M，Khanna，K.V，Peterson，P.K和Molitor，T.W，阿片和感染，JNeliroitninutiol，83(1998)4-18.Rivier，C，Rivier，J，Mormede，P和Vale，W，血管加压素和促肾上腺皮质激素释放因子在大鼠的促肾上腺皮质激素释放上的相互作用的性质的研究，Endocrino logy，115(1984)882-886.Rivier，C.L和Plotsky，P.M，促肾上腺皮质激素释放因子(CRF)介导的肾上腺垂体激素的分泌，Annir.Rev.Physiol，48(1986)475-494.Rossi，G.C，Leventhal，L和Pastemak，G.W，纳络酮敏感性orphaninFQ诱导的小鼠痛觉丧失，Eur.J.Pharrnacol，311(1996)R7-R8Sandin，J，Georgieva，J，Schott，P.A，Ogren，S.O和Terenius，L，海马内微注射Nociceptin/orphanin FQ损害了大鼠的空间学习能力，Elr.J.Neurosci，9(1997)194-197.Saperstein，A，Brand，H，Audhya，T，Nabriski，D，Hutchinson，B，Rosenzweig，S和Hollander，C.S，IL-1β通过促肾上腺皮质激素释放因子介导了应激诱发的免疫抑制，Endocrinolo，130(1992)152-158.Satoh，M和Minami，M，阿片类受体的分子药理学，Pharmacol.Ther，68(1995)343-364.Schwartz，T.W，J.Fuhlendorff，H，Langeland，J.C.T6gerson，S.P.Sheikh，(1989)，神经肽Y：XIV Nobel研讨会，ed：V Mutt；T.H6kfelt，K.Fuxe和J.M.Lundberg，Raven，N.Y.pp 143.Shavit，J.(1991)应激在动物中诱发的免疫调节：阿片和内源性阿片肽.In：R.Ader，D.L.Felten和N.Cohen(Eds.)，Psychoneuroimmunology，Vol.Academic Press，San Diego，pp.789-804.Shavit，Y，Depaulis，A，Martin，F.C，Terman，G.W，Pechnick，R.N，Zane，C.J，Gale，R.P和Lie beskind，J.C，脑内阿片受体参与了吗啡的免疫抑制作用，Proc.Natl.Acad.Sci.U.S.A，83(1986)7114-7117.Sheikh，S.P，R.HAkanson和T.W.Schwartz，(1989)，神经肽Y的Yj和Y2受体，FEBS Lett.245，209-214.Shippenberg，T.S，Bals，K.R和Herz，A，阿片类的动机特性：δ受体的激活介导强化过程的依据，Brain Res，436(1987)234-239.Simonin，F，Valverde，O，Smadja，C，Slowe，S，Kitchen，I，Dierich，A，Le-Meur，M，Roques，B.P，Maldonado，R和Kieffer，B.L，破坏小鼠的κ阿片类受体基因增强化学性内脏疼痛、削弱选择性κ激动剂U-50，488H的药理作用并减弱吗啡戒断症状，EMBO J，17(1998)886-897.Sora，I，Funada，M和Uh1，G.R，μ阿片类受体为[D-Pen2，D-Pen5]脑啡肽诱导的痛觉丧失所必需，Eur.J.Pharmacol，324(1997)R1-R2Stanley，B.G和Leibowitz，S.F，神经肽Y注射入下丘脑脑室周边：喂食行为的一种强刺激，Proc.Natl.Acad.Sci.U.S.A，82(1985)3940-3943.Stanley，B.G，Lanthier，D，Chin，A.S和Leibowitz，S.F，肾上腺切除或垂体切除对神经肽Y引发的进食的抑制：糖皮质激素的逆转，Brain Res，501(1989)32-36.Stefano，G.B，Salzet，B和Fricchione，G.L，无脊椎动物和脊椎动物的脑啡肽和阿片肽的结合：免疫激活和疼痛，Immunol.Today，19(1998)265-268.Tatemoto，K，Carlquist，M和Mutt，V，神经肽Y——一种与肽YY和胰多肽结构相似的脑内肽，Nature，296(1982)659-660.Tatemoto，K，神经肽Y：此脑内肽的完整氨基酸序列，Proc.Nadl.Acad.Sci.U.S.A，79(1982)5485-5489.Tejedor，R.P，Costela，C和Gibert，R.J，新生儿爱抚降低情绪反应性和对获得性无助感的易感性.涉及儿茶酚胺系统，Life Sci，62(1998)37-50.Tian，M，Broxmeyer，H.E，Fan，Y，Lai，Z，Zhang，S，Aronica，S，Cooper，S，Bigsby，R.M，Steinmetz，R，Engle，S.J，Mestek，A，Pollock，J.D，Lehman，M.N，Jansen，H.T，Ying，M，Stambrook，P.J，Tischfield，J.A和Yu，L，μ阿片类受体缺陷小鼠的造血、行为和性功能的改变，J.Exp*AIed，185(1997)1517-1522.Tortella，F.C和DeCoster，M.A，κ阿片类：在癫痫和CNS损伤中的治疗考虑，Clin.Neuropflarmacol，17(1994)403-416.Tsuda，M，Suzuki，T，Misawa，M和Nagase，H，阿片系统参与了安定在小鼠的抗焦虑作用，Eur.J.Pharmacol，307(1996)7-14.Uehara，Y，Shimizu，H，Ohtani，K，Sato，N和Mori，M，下丘脑促肾上腺皮质激素释放激素介导leptin引起食欲减退作用，Diabetes，47(1998)890-893.Vaughan，J，Donaldson，C，Bittencourt，J，Perrin，M.H，Lewis，K，Sutton，S，Chan，R，Tumbull，A.V，Lovejoy，D，Rivier，C等，Urocortin，一种与鱼urotensin I和促肾上腺皮质激素释放因子相关的哺乳动物神经肽[see comments，Nature，378(1995)287-292.Wahlestedt，C和Reis，D.J，神经肽Y相关性肽及其受体——受体是治疗药物的潜在靶向？Anne.Rez，Pharmacol.Toxicol，33(1993)309-352.Wahlestedt，C，N.Yanaihara和R.H.Akanson，(1986)，神经肽Y和相关性肽的不同的结合点前和结合点后受体的依据，Regul.Pep.13，307-318.Wahlestedt，C，Pich，E.Mi，Koob，G.F，Yee，F和Heilig，M，反义寡脱氧核苷酸对焦虑和神经肽Y-Y1受体的调节，Science，259(1993)528-531.Wettstein，J.G，Earley，B和Junien，J.L，神经肽Y的中枢神经系统药理学，Pharmacol T/ler，65(1995)397-414.Xu，X.J，Hao，J.X和Wiesenfeld，H.Z，Nociceptin或antinociceptin：大鼠的orphanin FQ/nociceptin的有效脊髓抗伤害效应，Neuroreport，7(1996)2092-2094.Zadina，J.E，Hackler，L，Ge，L.J和Kastin，A.J，一种有效的和选择性的内源性μ阿片受体激动剂[see comments，Nature，386(1997)499-502.Zhao，X.J，Hoheisel，G，Schauer，J和Bomstein，S.R，促肾上腺皮质激素释放神经激素结合蛋白及其在神经内分泌研究中的可能作用，Horm.Me表Res，29(1997)373-378.Zhu，Y和Im，W.B，抗惊厥药物U-54494A阻断小鼠神经母细胞瘤细胞的钠通道流动，J.Pharmacol.Erp.Trier，260(1992)110-116.
Claims (8)
1.吸诱素或吸诱素异构体的抑制剂在生产用于调节针对包括焦虑在内的应激的行为和/或神经学反应性的药物中的用途。
2.权利要求1的用途，其在于生产用于减少内源性的、定位于CNS的神经肽Y(NPY)以及其他具有类似特性的底物的降解的药物。
3.前述权利要求中任一项的用途，其在于生产用于治疗心身性、抑郁性和神经精神性疾病的药物。
4.权利要求3的用途，其特征在于所述心身性、抑郁性和神经精神性疾病选自焦虑症、抑郁症、失眠、慢性疲劳、精神分裂症、癫痫、进食障碍、痉挛和慢性疼痛。
5.前述权利要求中任一项的用途，其特征在于所述抑制剂与神经肽Y组合使用。
6.前述权利要求中任一项的用途，其特征在于所述抑制剂存在于一种具有生理学相容性的药物载体中。
7.前述权利要求中任一项的用途，其特征在于所述抑制剂被配制为所述抑制剂的前体药物。
8.前述权利要求中任一项的用途，其特征在于所述抑制剂通过肠道外、肠道内、口服、吸入或作为栓剂而使用。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24403600P | 2000-10-27 | 2000-10-27 | |
| US60/244,036 | 2000-10-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1471392A true CN1471392A (zh) | 2004-01-28 |
Family
ID=22921137
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA01817857XA Pending CN1471392A (zh) | 2000-10-27 | 2001-10-29 | 用于治疗神经性及神经心理性疾患的方法 |
| CNA2006101219115A Pending CN101143217A (zh) | 2000-10-27 | 2001-10-29 | 神经性和神经心理性疾病的治疗方法 |
| CNB018180671A Expired - Fee Related CN1278683C (zh) | 2000-10-27 | 2001-10-29 | 二肽基肽酶iv抑制剂在制备治疗焦虑症的药物中的用途 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2006101219115A Pending CN101143217A (zh) | 2000-10-27 | 2001-10-29 | 神经性和神经心理性疾病的治疗方法 |
| CNB018180671A Expired - Fee Related CN1278683C (zh) | 2000-10-27 | 2001-10-29 | 二肽基肽酶iv抑制剂在制备治疗焦虑症的药物中的用途 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20040043919A1 (zh) |
| EP (2) | EP1328271B1 (zh) |
| JP (2) | JP2004512299A (zh) |
| KR (2) | KR20040025875A (zh) |
| CN (3) | CN1471392A (zh) |
| AT (1) | ATE399008T1 (zh) |
| AU (3) | AU2002221773B2 (zh) |
| BR (2) | BR0114921A (zh) |
| CA (3) | CA2424475A1 (zh) |
| CY (1) | CY1108336T1 (zh) |
| DE (1) | DE60134563D1 (zh) |
| DK (1) | DK1328271T3 (zh) |
| ES (1) | ES2309108T3 (zh) |
| HK (1) | HK1062643A1 (zh) |
| IL (4) | IL155116A0 (zh) |
| NO (2) | NO20031849L (zh) |
| PT (1) | PT1328271E (zh) |
| RU (3) | RU2003115614A (zh) |
| WO (2) | WO2002034243A2 (zh) |
| ZA (2) | ZA200302590B (zh) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR200000815T2 (tr) * | 1997-09-29 | 2000-12-21 | Point Therapeutics Inc. | In vitro hematopoietik hücrelerin stimulasyonu. |
| US6979697B1 (en) * | 1998-08-21 | 2005-12-27 | Point Therapeutics, Inc. | Regulation of substrate activity |
| US6890904B1 (en) | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
| CA2424475A1 (en) * | 2000-10-27 | 2002-05-02 | Probiodrug Ag | Method for the treatment of neurological and neuropsychological disorders |
| US7132104B1 (en) | 2000-10-27 | 2006-11-07 | Probiodrug Ag | Modulation of central nervous system (CNS) dipeptidyl peptidase IV (DPIV) -like activity for the treatment of neurological and neuropsychological disorders |
| ES2339813T3 (es) | 2001-06-27 | 2010-05-25 | Glaxosmithkline Llc | Fluoropirrolidinas como inhibidores de dipeptidil peptidasas. |
| CA2481995A1 (en) | 2002-04-08 | 2003-10-16 | Torrent Pharmaceuticals Ltd. | Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors |
| US20050084490A1 (en) * | 2002-07-09 | 2005-04-21 | Point Therapeutics, Inc. | Boroproline compound combination therapy |
| JP4887139B2 (ja) | 2003-03-25 | 2012-02-29 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼインヒビター |
| CA2524009C (en) | 2003-05-05 | 2014-04-29 | Probiodrug Ag | Use of effectors of glutaminyl and glutamate cyclases |
| EP1961416B1 (en) | 2003-05-05 | 2013-01-23 | Probiodrug AG | Use of inhibitors of glutaminyl cyclase for treating psoriasis, rheumatoid arthritis or atherosclerosis. |
| US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| ZA200602051B (en) | 2003-08-13 | 2007-10-31 | Takeda Pharmaceutical | 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors |
| WO2005026148A1 (en) | 2003-09-08 | 2005-03-24 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| KR101121882B1 (ko) | 2003-10-15 | 2012-04-12 | 프로비오드룩 아게 | 글루타미닐 및 글루타메이트 사이클라제 이펙터의 용도 |
| US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| CN102134229B (zh) | 2004-03-15 | 2020-08-04 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
| US7687638B2 (en) | 2004-06-04 | 2010-03-30 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| US20060063719A1 (en) * | 2004-09-21 | 2006-03-23 | Point Therapeutics, Inc. | Methods for treating diabetes |
| EP1828192B1 (en) | 2004-12-21 | 2014-12-03 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| ZA200802857B (en) | 2005-09-14 | 2009-09-30 | Takeda Pharmaceutical | Dipeptidyl peptidase inhibitors for treating diabetes |
| CN102675221A (zh) | 2005-09-16 | 2012-09-19 | 武田药品工业株式会社 | 用于制备嘧啶二酮衍生物的方法中的中间体 |
| WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| EP2007734A1 (en) | 2006-04-12 | 2008-12-31 | Probiodrug AG | Enzyme inhibitors |
| US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
| TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
| US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
| JO2870B1 (en) | 2008-11-13 | 2015-03-15 | ميرك شارب اند دوهم كورب | Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes |
| KR20120092096A (ko) | 2009-09-02 | 2012-08-20 | 머크 샤프 앤드 돔 코포레이션 | 당뇨병의 치료 또는 예방을 위한 디펩티딜 펩티다제-ｉｖ 억제제로서의 아미노테트라히드로피란 |
| CN103664873B (zh) | 2009-12-30 | 2016-06-15 | 深圳信立泰药业股份有限公司 | 作为二肽基肽酶iv(dpp-iv)抑制剂的3-(3-氨基哌啶-1-基)-5-氧代-1,2,4-三嗪衍生物 |
| EP2538783B1 (en) | 2010-02-22 | 2016-06-01 | Merck Sharp & Dohme Corp. | Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes |
| US8980929B2 (en) | 2010-05-21 | 2015-03-17 | Merck Sharp & Dohme Corp. | Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes |
| US9073930B2 (en) | 2012-02-17 | 2015-07-07 | Merck Sharp & Dohme | Dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| US9668969B1 (en) | 2012-02-22 | 2017-06-06 | Arturo Solis Herrera | Methods of using QIAPINE |
| WO2014018350A1 (en) | 2012-07-23 | 2014-01-30 | Merck Sharp & Dohme Corp. | Treating diabetes with dipeptidyl peptidase-iv inhibitors |
| CN107213465A (zh) * | 2017-06-23 | 2017-09-29 | 武汉大学 | 二肽基肽酶iv抑制剂在制备防治癫痫的药物中的应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US25023A (en) * | 1859-08-09 | Improved device for making electro-magnetic currents, constant or intermittent | ||
| US2961377A (en) * | 1957-08-05 | 1960-11-22 | Us Vitamin Pharm Corp | Oral anti-diabetic compositions and methods |
| US3174901A (en) * | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
| US3879541A (en) * | 1970-03-03 | 1975-04-22 | Bayer Ag | Antihyperglycemic methods and compositions |
| US3960949A (en) * | 1971-04-02 | 1976-06-01 | Schering Aktiengesellschaft | 1,2-Biguanides |
| CH602612A5 (zh) * | 1974-10-11 | 1978-07-31 | Hoffmann La Roche | |
| US4935493A (en) * | 1987-10-06 | 1990-06-19 | E. I. Du Pont De Nemours And Company | Protease inhibitors |
| US5433955A (en) * | 1989-01-23 | 1995-07-18 | Akzo N.V. | Site specific in vivo activation of therapeutic drugs |
| US5462928A (en) * | 1990-04-14 | 1995-10-31 | New England Medical Center Hospitals, Inc. | Inhibitors of dipeptidyl-aminopeptidase type IV |
| IL106998A0 (en) * | 1992-09-17 | 1993-12-28 | Univ Florida | Brain-enhanced delivery of neuroactive peptides by sequential metabolism |
| IL111785A0 (en) * | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
| US5705483A (en) * | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
| US5543396A (en) * | 1994-04-28 | 1996-08-06 | Georgia Tech Research Corp. | Proline phosphonate derivatives |
| US5512549A (en) * | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
| US5614379A (en) * | 1995-04-26 | 1997-03-25 | Eli Lilly And Company | Process for preparing anti-obesity protein |
| DE19616486C5 (de) * | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
| US6006753A (en) * | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
| US5827898A (en) * | 1996-10-07 | 1998-10-27 | Shaman Pharmaceuticals, Inc. | Use of bisphenolic compounds to treat type II diabetes |
| US6011155A (en) * | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| US6803357B1 (en) * | 1998-02-02 | 2004-10-12 | New England Medical Center Hospitals, Inc. | Method of regulating glucose metabolism, and reagents related thereto |
| WO1999046272A1 (en) * | 1998-03-09 | 1999-09-16 | Fondatech Benelux N.V. | Serine peptidase modulators |
| DE19823831A1 (de) * | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
| DE19834591A1 (de) * | 1998-07-31 | 2000-02-03 | Probiodrug Ges Fuer Arzneim | Verfahren zur Steigerung des Blutglukosespiegels in Säugern |
| WO2000053171A1 (en) * | 1999-03-05 | 2000-09-14 | Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. | Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv |
| US6107317A (en) * | 1999-06-24 | 2000-08-22 | Novartis Ag | N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| US6172081B1 (en) * | 1999-06-24 | 2001-01-09 | Novartis Ag | Tetrahydroisoquinoline 3-carboxamide derivatives |
| US6110949A (en) * | 1999-06-24 | 2000-08-29 | Novartis Ag | N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| CA2400226C (en) * | 2000-03-31 | 2007-01-02 | Probiodrug Ag | Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
| CA2424475A1 (en) * | 2000-10-27 | 2002-05-02 | Probiodrug Ag | Method for the treatment of neurological and neuropsychological disorders |
-
2001
- 2001-10-29 CA CA002424475A patent/CA2424475A1/en not_active Abandoned
- 2001-10-29 RU RU2003115614/14A patent/RU2003115614A/ru not_active Application Discontinuation
- 2001-10-29 IL IL15511601A patent/IL155116A0/xx unknown
- 2001-10-29 CA CA002689012A patent/CA2689012A1/en not_active Abandoned
- 2001-10-29 AU AU2002221773A patent/AU2002221773B2/en not_active Ceased
- 2001-10-29 BR BR0114921-0A patent/BR0114921A/pt not_active Application Discontinuation
- 2001-10-29 EP EP01988583A patent/EP1328271B1/en not_active Expired - Lifetime
- 2001-10-29 ES ES01988583T patent/ES2309108T3/es not_active Expired - Lifetime
- 2001-10-29 JP JP2002537296A patent/JP2004512299A/ja not_active Withdrawn
- 2001-10-29 EP EP01988582A patent/EP1328270A2/en not_active Withdrawn
- 2001-10-29 DK DK01988583T patent/DK1328271T3/da active
- 2001-10-29 RU RU2003115622/14A patent/RU2286149C2/ru not_active IP Right Cessation
- 2001-10-29 AU AU2177302A patent/AU2177302A/xx active Pending
- 2001-10-29 ZA ZA200302590A patent/ZA200302590B/en unknown
- 2001-10-29 WO PCT/EP2001/012479 patent/WO2002034243A2/en active Application Filing
- 2001-10-29 WO PCT/EP2001/012478 patent/WO2002034242A2/en not_active Application Discontinuation
- 2001-10-29 CN CNA01817857XA patent/CN1471392A/zh active Pending
- 2001-10-29 CA CA2422889A patent/CA2422889C/en not_active Expired - Fee Related
- 2001-10-29 BR BR0114924-5A patent/BR0114924A/pt not_active IP Right Cessation
- 2001-10-29 AT AT01988583T patent/ATE399008T1/de active
- 2001-10-29 KR KR10-2003-7005718A patent/KR20040025875A/ko not_active Application Discontinuation
- 2001-10-29 US US10/415,263 patent/US20040043919A1/en not_active Abandoned
- 2001-10-29 AU AU2002227898A patent/AU2002227898A1/en not_active Abandoned
- 2001-10-29 CN CNA2006101219115A patent/CN101143217A/zh active Pending
- 2001-10-29 CN CNB018180671A patent/CN1278683C/zh not_active Expired - Fee Related
- 2001-10-29 KR KR10-2003-7005769A patent/KR20030096227A/ko not_active Application Discontinuation
- 2001-10-29 IL IL15515701A patent/IL155157A0/xx unknown
- 2001-10-29 PT PT01988583T patent/PT1328271E/pt unknown
- 2001-10-29 DE DE60134563T patent/DE60134563D1/de not_active Expired - Lifetime
- 2001-10-29 JP JP2002537297A patent/JP2004512300A/ja active Pending
- 2001-10-29 ZA ZA200302394A patent/ZA200302394B/en unknown
-
2003
- 2003-03-27 IL IL155116A patent/IL155116A/en not_active IP Right Cessation
- 2003-04-24 NO NO20031849A patent/NO20031849L/no unknown
- 2003-04-25 NO NO20031867A patent/NO20031867L/no not_active Application Discontinuation
-
2004
- 2004-07-27 HK HK04105537A patent/HK1062643A1/xx not_active IP Right Cessation
-
2006
- 2006-06-20 RU RU2006122179/15A patent/RU2416406C2/ru not_active IP Right Cessation
-
2008
- 2008-09-11 CY CY20081100982T patent/CY1108336T1/el unknown
-
2009
- 2009-02-11 IL IL196994A patent/IL196994A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1471392A (zh) | 用于治疗神经性及神经心理性疾患的方法 | |
| CA2630624C (en) | Compositions and methods for increasing insulin sensitivity | |
| JP5114381B2 (ja) | 精神疾患および障害治療用アミリンおよびアミリンアゴニスト | |
| JP5727642B2 (ja) | センタキンを用いた新規の治療方法 | |
| KR20180001581A (ko) | 정신 의학적 증상의 치료를 위한 ｄ-메타돈 | |
| AU2014342520B2 (en) | Novel treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder | |
| JP2009526833A (ja) | 代替療法を最適化し、薬局方を全体的な嗜癖の治療に拡大適用するための新規な薬剤組成物 | |
| WO2014113564A1 (en) | New itch treatment using a combination of neurokinin-1, gastrin releasing peptide, and glutamate receptor antagonists | |
| US20090186818A1 (en) | Therapeutic Method for Glycaemic Control | |
| Arulmani | Calcitonin Gene-Related Peptide and Migraine: Implications for Therapy | |
| AU2006201186B2 (en) | Method for the treatment of neurological and neuropsychological disorders | |
| NZ718978B2 (en) | Novel treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1062644 Country of ref document: HK |
|
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1062644 Country of ref document: HK |